subscribeSubscribe
price-trendAsk Us
Acadia`s Trofinetide NDS For Rett Accepted, Priority Review

Acadia`s Trofinetide NDS For Rett Accepted, Priority Review
BUSINESSWIRE
22 Apr 2024
Share Share
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study
BUSINESSWIRE
08 Jun 2023
Share Share
Acadia Pharma Announces DAYBUE™ (trofinetide) is Now Available

Acadia Pharma Announces DAYBUE™ (trofinetide) is Now Available
BUSINESSWIRE
17 Apr 2023
Share Share
Acadia Announces Trofinetide NDA has been Accepted for Filing & Review by USFDA

Acadia Announces Trofinetide NDA has been Accepted for Filing & Review by USFDA
BUSINESSWIRE
12 Sep 2022
Share Share
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
BUSINESS WIRE
08 Aug 2022
Share Share
Acadia Pharmaceuticals Submits NDA to the U.S. FDA for Trofinetide

Acadia Pharmaceuticals Submits NDA to the U.S. FDA for Trofinetide
BUSINESSWIRE
18 Jul 2022
Share Share
Acadia touts late-stage win for its Rett syndrome drug

Acadia touts late-stage win for its Rett syndrome drug
K. Blankenship ENDPTS
08 Dec 2021
Share Share
ACADIA Initiates Ph3 Pivotal Study of Trofinetide in Rett Syndrome

ACADIA Initiates Ph3 Pivotal Study of Trofinetide in Rett Syndrome
BUSINESSWIRE
31 Oct 2019
Share Share
ACADIA`s Initiates Ph3 Pivotal Study of Trofinetide in Rett Syndrome

ACADIA`s Initiates Ph3 Pivotal Study of Trofinetide in Rett Syndrome
BUSINESSWIRE
30 Oct 2019
Share Share
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome
BUSINESSWIRE
28 Mar 2019
Share Share